iiinova — where your digital self keeps evolving

Hannah R. Abrams @hannahrabrams.bsky.social · 12/09/2026

I learn something every time I read papers by oncology PharmDs. This @JCOOP_ASCO letter talks through discrepant findings between 2 studies of taxane titration. It would be great to save patients time-in-chair, but there are still some key concerns: ascopubs.org/doi/pdf/10.1...

020

Hannah R. Abrams @hannahrabrams.bsky.social · 09/09/2026

What's unique about financial toxicity in pediatric cancer settings? - Effect on siblings, costs of both food + babysitting for other kids & lost wages - Long-term financial effects for young families at a fragile time - Often using crowdfunding, eg GoFundMe, to help ascopubs.org/doi/pdf/10.1...

0134

Hannah R. Abrams @hannahrabrams.bsky.social · 24/07/2026

To a non-expert, this seems to be a neat new tool: Google can now create and export isochrones (maps of the space within a given travel time from a point) from a given point. Here's the space within 30 minutes of Seattle's trauma hospital (Harborview), for ex. developers.google.com/maps/documen...

Information page for Isochrones API.The Isochrones API calculates the area that a person can reach from a specific origin point within a set amount of time. Unlike a radius, which measures a straight-line distance, an isochrone accounts for actual road network travel times to create a polygon that represents true reachability.

Common use cases include:

Delivery logistics: Determine which customers are servable within 30 minutes of a warehouse.
Real estate: Find properties within a 45-minute commute of a workplace.
Urban planning: Analyze the accessibility of essential services like hospitals or grocery stores.
To get started, see Set up the Isochrones API.

30 minute isochrone for Harborview Medical Center

051

Hannah R. Abrams @hannahrabrams.bsky.social · 25/06/2026

Managing bone health in breast cancer survivors on aromatase inhibitors: comprehensive review out now in JCO OP! @jessicaallenmd.bsky.social ascopubs.org/doi/full/10....

010

Hannah R. Abrams @hannahrabrams.bsky.social · 22/06/2026

...And in a world of near universal prior auth for cancer drugs regardless (@michaelannica.bsky.social @fumikochino.bsky.social), unclear that MA vs traditional sees a big difference there.

010

Hannah R. Abrams @hannahrabrams.bsky.social · 22/06/2026

Nice editorial @thewonkologist.bsky.social & Dr. Nancy Keating about revisiting our priors re: Medicare Advantage for cancer care. While there is reason to be cautious and investigate, current data on MA vs traditional medicare in cancer is far from conclusive. ascopubs.org/doi/10.1200/...

142

Hannah R. Abrams @hannahrabrams.bsky.social · 21/06/2026

Did not know cancer centers can technically now bill for patient navigation. I agree with the patients interviewed here: navigation is extremely high-value, and also I do not think it should be behind a paywall. ascopubs.org/doi/10.1200/...

220

Hannah R. Abrams @hannahrabrams.bsky.social · 20/06/2026

Waiting for clinical teams to order NGS slows down turnaround time by 2 weeks on average. It's time for insurance companies & cancer centers to work together & set up automatic pipelines in these situations, so patients don't have a long anxious wait to start treatment. ascopubs.org/doi/10.1200/...

Fig 2. (A) TAT intervals and definitions. (B) and (E) Yearly NSCLC CGP TAT and trend analysis (2018-2024). Boxes indicate median TAT, and whiskers indicate IQR. Dotted lines are linear trendlines: (B) overall TAT [Y = –1.154 × X + 2,361.0], (C) ordering TAT [Y = 0.2143 × X – 419.5], (D) specimen TAT [Y = –0.1357 × X + 279.0], and (E) molecular TAT [Y = –1.079 × X + 2,190.0]. P values reflect linear regression analysis (*P < .05, **P < .01, ***P < .001). CGP, comprehensive genomic profiling; NSCLC, non–small cell lung cancer; TAT, turnaround time.

011

Hannah R. Abrams @hannahrabrams.bsky.social · 18/06/2026

Midjourney has announced they're developing a full-body 60 second "ultrasonic CT". I want better & cheaper imaging. But the idea that: 50K scanners x 720 min x 30d = 1 billion scans/mo Seems totally unaware of supply/demand, logistical constraints of getting people in/out, & privacy concerns

100

Hannah R. Abrams @hannahrabrams.bsky.social · 03/06/2026

On the #ASCO26 hot topics of KRAS and toxicity: systematic review & meta-analysis in JCO OP of sotorasib dosing shows trend to improved PFS with LOWER dosing. Less toxicity -> longer time on-treatment? @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

050

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

Key #desmoid tumor takeaways from RINGSIDE presentation (varegacestat) #ASCO26 #sarcoma today: - ORR 55.7%, remainder largely shrunk but under 30% - Quick time to pain improvement - only 4 weeks in many - 80% need for dose reduction primarily d/t diarrhea

010

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

JCO OP at #ASCO26: Follow up yesterday's session, "Cancer Care in Times of Crisis and in Immigrant and Displaced Populations." Full case discussion out now @jco-asco.bsky.social: ascopubs.org/doi/10.1200/...

010

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

#ASCO26 Abstract 12160: impressive effort to review charts of n = 848 patients for whether corticosteroids for irAE → worse cancer outcomes. Adds to/confirms existing literature in this area suggesting the concern is really with high doses.

Impact of corticosteroid exposure on long-term immune checkpoint in- hibitor responses in solid tumors. First Author: Theresa Medina, University of Colorado, Aurora, CO. Text beyond allowed length; summary: The steroid exposure was defined as very high if prednisone (or equivalent) ≥ 20mg/day and length of exposure was ≥ 42 days. 64.8% of patients experienced an irAE and 44.7% of patients developed G3-4 irAE requiring corticosteroids +/- steroid sparing agent. The low impact corticosteroid exposure did not affect PFS, OS or tumor specific survival. The very high impact CS exposure was associated with decrease in PFS (p = 0.02) but not with OS or TSS (p = 0.3). The high impact steroid sparing agent was associated with decrease in PFS (not significant) but the very high impact steroid sparing agent was associated with decrease in PFS. The chronic irAE was associated with slight improvement in PFS (not significant).

110

Hannah R. Abrams @hannahrabrams.bsky.social · 29/05/2026

3. BCG + CIT: Knew from the abstract: pCR 68%, 42% had any BCG tox, 9% G3. Paper adds: while largely comprehensive, notably 20% of ITT didn’t get all doses of rBCG Would love to hear from bladder experts what your thoughts were now that the full paper is out! #ASCO26 ascopubs.org/doi/pdf/10.1...

010

Hannah R. Abrams @hannahrabrams.bsky.social · 29/05/2026

Paper adds: Forest plot w/o other clear predictors of response. Re: huge difference between κ and ƛ AL, anselamimab was generated w/ kappa isotype immunogen. KMs for overall vs κ-only & ƛ-only pop below! #ASCO26 ascopubs.org/doi/10.1200/...

Fig 2. Kaplan-Meier analysis of time to ACM in the (A) overall population, (B) patients with the kappa isotype, and (C) patients with the lambda isotype. Censor events are shown by vertical tick marks. ACM, all-cause mortality; PCD, plasma cell dyscrasia.

100

Hannah R. Abrams @hannahrabrams.bsky.social · 29/05/2026

What can we tell folks w/ taxane-induced peripheral neuropathy after early-stage cancer re: whether it will recover? @SWOG.org 1714, #ASCO26 abs 12117: - Of 1321 pts, 553 had TIPN at end of tx. - 48.5%, it improved - 33.8% didn't change - 17.7% worsened @drdawnhershman.bsky.social #survivorship

020

Hannah R. Abrams @hannahrabrams.bsky.social · 27/05/2026

Tips for fellows going to their first #ASCO26 (as I prepare to go to my whole of... second): Google "mccormick place floor plan" and pick your favorite version of the map to save to your phone. I'm sure the blue 3D one works for some people, but it does not for me! 😂

120

Hannah R. Abrams @hannahrabrams.bsky.social · 23/05/2026

It's not in your head: prior auth has increased over the past 10 years in oncology. (Though not as much as other specialties.) @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

120

Hannah R. Abrams @hannahrabrams.bsky.social · 21/05/2026

We have a lot of mechanisms to prevent OVER dosing of chemotherapy. This week in #JCOOP, Dr. Ruth Choa & colleagues outline a case in which an EMR error led a patient to receive an UNDER dose -only 50%- for 4/8 cycles of curative-intent treatment. @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

Inadvertent Dose Reduction of Chemotherapy in a Patient Receiving Multiagent Neoadjuvant Chemotherapy
Authors: Ruth E. Choa, MD, PhD https://orcid.org/0000-0002-4798-7565 ruth_choa@dfci.harvard.edu, Kevin H. Lin, MD, PhD, Matthew L. Meizlish, MD, PhD https://orcid.org/0000-0002-4306-5061, Christof C. Smith, MD, PhD https://orcid.org/0000-0001-6517-0439, Katherine J. Feder, MD, MS, and Joseph O. Jacobson, MD, MSc

...AL elected to proceed with chemotherapy but was concerned about the acute toxicity of one of the agents. To accommodate these concerns, he and his oncologist decided on a modified regimen in which the agent is administered in divided doses, with half doses administered on days 1 and 2 rather than the full dose on Day 1. The intention was to use this split-dosing strategy for the first cycle, then resume standard chemotherapy for cycle 2 if the treatment was tolerated. However, day 2 of the order was accidentally deleted from the chemotherapy plan, and AL inadvertently received only half of the intended dose of the agent. Patient, provider, and pharmacy team all missed catching this error in the first cycle. Using the short-cut copy-forward function of the computerized prescriber order entry system (CPOE) of a proprietary electronic health record (EHR), the error was propagated forward for an additional 2 cycles until cycle 4 of the 8 planned cycles.

030

Hannah R. Abrams @hannahrabrams.bsky.social · 18/05/2026

340B as it exists now is crucial to oncology care. In JCO OP this month, @ascocancer.bsky.social releases updated policy recommendations for reform of the program: ascopubs.org/doi/10.1200/... @jco-asco.bsky.social

Title of article: 340B Drug Pricing Program: An Updated ASCO
Policy Statement

Authors:
Blase Polite, MD, MPP, FASCO 1 ; Niharika Dixit, MD 2 ; John Hennessy, BCPA 3 ; Marissa Rivera, MBA 4 ; Ashley Sumrall, MD, FACP, FASCO 5 ;
Wade Swenson, MD, MPH, MBA, FACP 6 ; Kashyap Patel, MD 7 ; Natalie Dickson, MD, MMHC, FACP 8 ; Jonathan Phillips, MPH 9 ;
Azam Masood, MPH 9 ; and Allyn Moushey, MSW 9

TABLE 2. ASCO Policy Recommendations for Reforming the 340B Drug Pricing Program
Changes to program eligibility
A new formula to determine 340B eligibility for non–hospital-af liated providers should be established. We suggest dividing the number of Medicaid,
uninsured, and dual-eligible patients by total patient visits (under a single TIN) to create a new measure known as the indigent care ratio
Independent oncology practices with multiple locations should be able to register a child site for the 340B Program as long as they bill under the same Tax ID
(TIN) as the eligible parent practice
ASCO supports reforms to ensure a covered entity’s right to engage multiple contract pharmacies. We recommend capping fees paid to contract
pharmacies and TPAs and establishing a civil monetary penalty for excessive fees
Transparency and accountability
Increase reporting and auditing requirements for 340B entities
Any institution accessing 340B discounts should be required to demonstrate they substantially meet the nancial assistance policy criteria outlined in IRS
501(r)
New civil monetary penalties (CMPs) should be broadened to include entities that fail to demonstrate transparency and adherence to requirements for
limiting patient nancial liability and directing savings back into direct patient care. Existing CMPs for manufacturers should remain in place and be
strengthened
End the exclusion of orphan drugs from 340B pricing for certain entities such as CAHs
Avoid narrowing the patient de nition to exclude insured patients and instead develop a de nition that would require the covered entity to have an ongoing
clinical relationship with the patient
Other nancial reforms
The HHS secretary or federal policymakers should either appropriate funds or implement other funding mechanisms to support reformed program oversight
and operations
Abbreviations: CAH, critical access hospitals; TPA, third-party administrator.

010

Hannah R. Abrams @hannahrabrams.bsky.social · 24/03/2026

Should we be reserving stem cells for every patient with #myeloma treated with BCMA CAR T? Reduces severe infections by over half, but >4x cost. Need risk-stratification (or IVIG) to make sustainable. Cost effectiveness modeling in #JCOCCI : ascopubs.org/doi/10.1200/... @ziadbakouny.bsky.social

Title page and abstract:
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma
Ehsan Malek, MD 1 ; Brian Betts, MD 1 ; Megan Herr, PhD 1 ; Marco Davila, MD 1 ; Shernan Holtan, MD 1 ; James J. Driscoll, MD, PhD 2,3 ; and Han Yu, PhD 1

FIG 3. Cost breakdown by strategy. Stacked bar chart of per-patient costs for the no-boost and boost
strategies. In the no-boost arm, all costs are attributable to hospitalization for infection. In the boost
arm, upfront reserve collection accounts for the majority of costs, while infection-related costs are
markedly lower. Total costs for each strategy represent the sum of upfront collection/storage fees
and longitudinal infection-related hospitalization costs. USD, US dollars.

Figure demonstrates cost per patient >$20,000 in boost group, under $5000 in no boost group. Majority of costs attributable to cost of stem cell collection up-front.

131

Hannah R. Abrams @hannahrabrams.bsky.social · 22/03/2026

This is cool: fullerenes, these neat carbon structures discovered in 1985 @ Rice University, significantly reduced incidence of radiation dermatitis in people with head & neck cancer getting radiation. Tx groups not perfectly matched, but encouraging study. ascopubs.org/doi/10.1200/...

010

Hannah R. Abrams @hannahrabrams.bsky.social · 21/03/2026

2. How do people living in low broadband access areas feel about Telehealth visits? Surprisingly open - and asking for more proactive outreach. ascopubs.org/doi/10.1200/...

Table 3. Practice Implications for Oncology Providers in Low-Broadband Settings
Practice Domain Key Implication
Proactive Offering Proactively offer VTVs even in low-broadband regions; patients may adopt VTV when given the option
Modality Matching Reserve in-person care for essential physical examinations, labs, transfusions, or imaging, while offering VTV for follow-ups, counseling, and routine check-ins
Situational Flexibility Frame VTV as a safe and practical alternative, especially, during adverse weather, long travel distances, or out-of-state circumstances
Digital Readiness Build digital comfort through low-stakes trial runs, patient portal tutorials, or staff-led technology coaching to reduce first-visit barriers
Relational Care Validate patients' preference for face-to-face care while emphasizing strategies to maintain connection, attention, and trust during VTV
Future Planning Normalize VTV as a scalable option that patients may increasingly rely on with aging, mobility limitations, or worsening weather conditions

000

Hannah R. Abrams @hannahrabrams.bsky.social · 21/03/2026

Two important patient-perspective studies JCO OP @jco-asco.bsky.social this week: 1. What do people w/ advanced cancer participating in early-phase clinical trials (ie, Phase 1) understand about their prognosis? 27% believe cancer is curable 38% report never discussing prognosis w/ oncologist.

TABLE 2. Participant-Reported Measures: Prognostic Perceptions and
Hope at the Time of Phase I Clinical Trial Enrollment
27.4% report goal of cancer treatment is to cure cancer, 40% describe themselves as not terminally ill, and 37.8% report never or rarely discussing prognosis with oncologist.

110

Hannah R. Abrams @hannahrabrams.bsky.social · 16/03/2026

Broken incentives: when a $3K/year cancer treatment may cost patients more than a $200K/year one. 💸 Why isn't structured exercise getting the uptake it should? Follow up in @jco-asco.bsky.social on economics of #ChallengeTrial @csoncol.bsky.social ascopubs.org/doi/pdf/10.1...

Title: Economics of Translating Research Into Practice: The Case of
Exercise to Prevent Cancer Recurrence
Allan S. Detsky, MD, PhD 1,2,3 ; Kerry S. Courneya, PhD 4 ; Christopher M. Booth, MD 5 ; and Shivan J. Mehta, MD, MBA, MSHP 6,7

Finally, there is a distinct appeal of an exercise program for
patients and family members because of its effectiveness,
low toxicity, and broad accessibility. However, this appeal
depends on how it is paid for and framed. If they are faced
with direct costs because of the lack of insurance coverage,
they may never adopt it because people are price sensitive in
their health care purchase decisions. There is also the be-
havioral bias that patients and clinicians have toward drugs.
Through the availability heuristic, they may only see medical
therapies as helping in their ability to ght cancer. Thus,
they may not fully engage in exercise or be willing to pay
much out of pocket.
The results of the CHALLENGE trial have issued a challenge to
parties that fund and insure health care costs. Are they willing
to fund interventions beyond drugs, devices, and traditional
medical procedures that show comparable effectiveness and
are likely more economically attractive? The economic issues
related to this discovery raises a paradox: It may in fact be
easier to implement a new anticancer medicine with serious
side effects that costs $200,000 USD/year (where the pro t
motive, pathways to implementation and relationships be-
tween the interested parties are well known and previously
traveled) than a much more economically attractive program
of structured exercise proven to be effective in a rigorously
conducted large randomized trial that breaks new ground (ie,
shows an overall survival bene t). That is, it is easier to be
practice-changing than paradigm-changing.

021

Hannah R. Abrams @hannahrabrams.bsky.social · 26/02/2026

Why aren't docs using code G2211? G2211 is a new billing code for longitudinal care of complex conditions, but overall MDs are using it ~25% the rate anticipated. Other pay was adjusted to make room, so this is in net a loss to MDs providing continuity of care - the thing we want.

Fig 2. Medicare projected versus actual utilization of G2211. All physicians were anticipated to report 83.7 million uses of the code but only reported 24.7. Hematology/oncology physicians expected to report 3.2 million but only reported 1.6 million.

120

Hannah R. Abrams @hannahrabrams.bsky.social · 05/02/2026

It's taken over 10 years for an erroneous reference to (almost) make it out of the citation chain. Less about the reference itself (incorrect claim re: cisplatin ototoxicity) and more about our science. Case report here @jco-asco.bsky.social: ascopubs.org/doi/10.1200/...

Fig 1. Reference characteristics to the article by Ross et al by year of publication. Stacked area chart depicting the distribution of citation characteristics referencing the article by Ross et al, categorized by publication year (2010-2025). Each color represents a distinct citation characteristic: Affirmative, contrastive, assumptive, conceptual, methodologic, perfunctory, and negative. Vertical dashed lines mark two key regulatory events: the 2011 cisplatin label update and the 2015 label revision.

010

Hannah R. Abrams @hannahrabrams.bsky.social · 01/02/2026

"Curative hope" in oligometastatic breast cancer: ~50% of surveyed US medical oncologists recommend consolidative tx to all cancer sites. It's a brave new world, and a setting where patients often deserve to get second/multiple opinions! @jco-asco.bsky.social #OncSky ascopubs.org/doi/10.1200/...

010

Hannah R. Abrams @hannahrabrams.bsky.social · 31/01/2026

Time from cancer diagnosis → treatment is rising: 21 days in 2004 to 28 days in 2015. Much of this is because of ⬆️ in stage 1 & there may be some good reasons - eg careful shared-decision making & planning. But how do we support people during the (often) anxious wait? ascopubs.org/doi/full/10....

010

Hannah R. Abrams @hannahrabrams.bsky.social · 31/01/2026

If you're interested in learning more about how we might reduce overuse/waste, we wrote this review in @jco-asco.bsky.social JCO OP including some of the earlier low-dose nivo data, and I also highly recommend oncdoc.org for oral oncology drugs. ascopubs.org/doi/10.1200/...

000

Hannah R. Abrams @hannahrabrams.bsky.social · 31/01/2026

2. Xeloda (capecitabine) was approved in 1998, & in 2025 FDA has added a black box warning to test for DPYD variants. As we catch up to a pharmacogenomic era, Mark Ratain & Peter O'Donnell summarize the dire need for data: when you find a variant, what dose to Rx? Helpfully, they provide some recs:

100

Hannah R. Abrams @hannahrabrams.bsky.social · 31/01/2026

"What dose?" is the name of the game this week @jco-asco.bsky.social as ghosts of 2000s haunt modern oncology. 1. We've known since 2010 nivo is active at low doses/long intervals. This week Vanita Noronha & team show just 20mg (vs 240mg) is active in 5 ca types. ascopubs.org/doi/10.1200/...

120

Hannah R. Abrams @hannahrabrams.bsky.social · 29/01/2026

#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel. Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts? A: Largely, no! Similar communication, slight ⬆️ appts. ascopubs.org/doi/full/10....

153

Hannah R. Abrams @hannahrabrams.bsky.social · 28/01/2026

In this small pilot study, #PanCan pancreatic cancer patients randomized to receive medical cannabis while starting chemotherapy had improvement in pain (44% vs 20%), appetite (56% vs 30%), and insomnia (67% vs 30%).

120

Hannah R. Abrams @hannahrabrams.bsky.social · 27/01/2026

Where are US patients with cancer traveling for care? Medicare claims analyzed in JCO CCI: unsurprisingly, community-based networks carry a large load. Notably, confined to 12h drive & unclear how satellite sites included, but a close look at the map may surprise you: ascopubs.org/doi/10.1200/...

1122

Hannah R. Abrams @hannahrabrams.bsky.social · 26/01/2026

From theory to practice: in #JCOOP, a conceptual model to describe how practices cope with losing a rural oncologist - and a new podcast interview with @fumikochino.bsky.social to really dive into a real-world example. #HealthPolicy

FIG 1. The inferred relationships between theme components.

010

Hannah R. Abrams @hannahrabrams.bsky.social · 26/01/2026

Just adding a "🚩 suspected cancer" flag reduced the time from referral to appointment by over 50%(and dropped the time from referral -> diagnosis of cancer by 63 days) @nychealthsystem.bsky.social @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

Fig A3. Improvements in efficiency of care by age.

120

Hannah R. Abrams @hannahrabrams.bsky.social · 17/01/2026

How important is #HCT donor age in the #PTCy era? Large single-center study in JCO OP raises the question of how strongly age should be prioritized: ascopubs.org/doi/10.1200/... @EJShpallMD

Fig 1. Association of donor age with OS. (A) The plot shows the unadjusted HR for death according to donor age. A linear model (red line) is compared with a more flexible spline model (blue line), which allows for a non-linear relationship. Shaded ribbons represent 95% CIs. The similarity between the two models and the fact that their CIs consistently overlap an HR of 1.0 indicates that there is no significant linear or nonlinear association between donor age and survival in this cohort. (B) Kaplan-Meier analysis of OS stratified by dichotomized donor age: donors younger than 32 years (red) versus those 32 years and older (blue). There was no statistically significant difference in survival between the two groups (log-rank P = .51). HR, hazard ratio; OS, overall survival.

020

Hannah R. Abrams @hannahrabrams.bsky.social · 14/01/2026

SNF capacity is the bottleneck that keeps people waiting in ER hallways and make-shift hospital rooms. SNF beds are crucial to our health system. Since 2020, capacity is down 5%, with less slack, due to staffing shortages. @jamainternalmed.com @mlbarnett.bsky.social: jamanetwork.com/journals/jam...

053

Hannah R. Abrams @hannahrabrams.bsky.social · 21/12/2025

🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding. Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!

Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor.

Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.

Proposed Action

We propose the following approaches to make early ToDA of ICI feasible in daily routine practice:
•
ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment;
•
AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center);
•
ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended;
•
ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs;
•
ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.

131

Hannah R. Abrams @hannahrabrams.bsky.social · 20/12/2025

Potential for cure in metastatic gastric cancer with actionable biomarkers? - 51 pts/1710 treated over 9 years in Japan - "Potential cure" = PFS >3 years, NED, >1 year since last tx w/o progression (consolidative surgery allowed) - dMMR 23%, CPS ≥10 30%, HER2+ 24% ascopubs.org/doi/10.1200/...

030

Hannah R. Abrams @hannahrabrams.bsky.social · 20/12/2025

What are outcomes w/ histotripsy for liver tumors/mets in real world since FDA approval in 12/2023? Out now in #JCOOP: at 3 mo, ~95% local control, 7% distant POD. Need longer term data, not enough to distinguish b/w local control options, but helpful to have a start. ascopubs.org/doi/10.1200/...

Fig 1. (A and B) Thirty- and 90-day outcomes of intended complete treatment with histotripsy by histologic tumor treated and (C) time-to-event analysis for primary versus secondary malignancy. CCA, cholangiocarcinoma; CRLM, common cancer, with liver metastasis; HCC, hepatocellular carcinoma; HNSC, head and neck squamous cell; NET, neuroendocrine tumor; PDAC, pancreatic ductal adenocarcinoma.

010

Hannah R. Abrams @hannahrabrams.bsky.social · 19/12/2025

Sure, I've heard of that, but have you heard about

Image of Victor Wembanyama, star of the San Antonio Spurs, over an image of a burr cell

030

Hannah R. Abrams @hannahrabrams.bsky.social · 18/12/2025

Really important perspective from Ramy Sedhom on FOLFIRINOX in #panCAN patients >70 years old ("OA"). Even in selected patients who receive this intensive regimen, even w/ preemptive dose reductions, 56% G3 AE or unplanned hospitalization. ascopubs.org/doi/10.1200/... #JCOOP #GIOnc

At first glance, Collineau's findings seem to be predictable: FOLFIRINOX is toxic, and OAs are vulnerable. But the deeper issue is whether we are asking the right question. By focusing narrowly on which OA can endure FOLFIRINOX, we risk missing the more relevant point: what is the most tolerable approach to the care of OAs with PDAC, and who truly benefits?
The Edison analogy is instructive here. His lasting legacy was not the brightest bulb, but the system that made light usable, safe, and enduring. In PDAC, the lesson is similar: the discovery of an intense regimen is useless unless it is embedded in a system that makes treatment tolerable and meaningful for patients. For OAs, that grid is built through geriatric assessment (GA), supportive interventions (nutrition, prehabilitation, psychosocial support), and integration of palliative care.

From “Who Can Tolerate” to “Who Will Benefit”

It is time for all of us to reimagine PDAC care in OA. The central question is no longer “who can tolerate FOLFIRINOX,” but “who will truly benefit?” Answering that requires
1.
Routine GA to uncover vulnerabilities
2.
Supportive interventions (comorbidity management, exercise, psychosocial support, nutritional support, and palliative integration) to enhance resilience
3.
Trial designs that embed tolerability and quality of life as end points that complement response and survival
4.
Exploration of objective aging biomarkers (inflammation, senescence, aging clocks, sarcopenia) for future stratification

021

Hannah R. Abrams @hannahrabrams.bsky.social · 17/12/2025

Significant overestimation of renal function by eGFR compared to measured CrCl in people with nonmetastatic RCC (including Cys C-adjusted). Wide implications re: cystectomy cutoffs. #UroSky #NephSky is this part of your practice for people near cutoff? ascopubs.org/doi/10.1200/... #MedSky #JCOOP

At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/min/1.73 m2

Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance

Full abstract beyond alt text limits but is available publicly at https://ascopubs.org/doi/10.1200/OP-25-00895

Highlighting Methods and Results:
Methods

In this prospective study, 72 patients with nonmetastatic RCC undergoing preoperative evaluation completed serum creatinine, cystatin C, and 24-hour urine collections. eGFR values were calculated using multiple established equations, both race-inclusive and race-neutral. The agreement between eGFR and measured GFR was assessed using Passing-Bablok regression. Linear regression estimated the discrepancy between eGFR and measured GFR at clinically relevant cutoffs of 45 and 60 mL/min/1.73 m2.
Results

Across all equations, eGFR consistently overestimated renal function compared with measured GFR. At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/m

072

Hannah R. Abrams @hannahrabrams.bsky.social · 16/12/2025

Adding to this - #Roon for doctors is launching in oncology today! Here's an example of how the format looks discussing #SABCS25. Join at www.roon.com.

100

Hannah R. Abrams @hannahrabrams.bsky.social · 16/12/2025

What financial advice do those who've survived AYA cancers give to people going through it now? In #JCOOP this week (among other insights), led by Tim Ohlsen @seattlechildrens.org Notably, they highlight how much fear of future cost increases hangs over survivors. ascopubs.org/doi/full/10....

Table of employment and financial support recommendations from survivors by time period.

Across the care continuum: Consider jobs that cover financial and insurance needs
Set up a health savings account, contribute a small amount from each paycheck to help pay medical bills
Ask for help from the care team, especially hospital social worker and use hospital billing department regarding cancer-related finances and resources
Seek college scholarships
During active therapy
Explore short-term disability or other benefits offered by employer
Consider ways to cut nonmedical expenses
Seek financial assistance grants
Set up a payment plan
Learn/connect with other YAs on how they handled finances and cancer
Early in survivorship Maintain employment with stable health insurance coverage
Build financial literacy
Seek vocational counseling to mitigate cancer-related job impacts
Save money to account for rising cost of living and possible future medical costs

Saving, or “stockpiling” money (diagnosed 0-17 years; 21 years since diagnosis) was important to some interview participants on the basis of their cancer history, to cover future medical expenses, including the possibility of recurrence.

030

Hannah R. Abrams @hannahrabrams.bsky.social · 09/12/2025

Spend-downs are also not equally distributed & are more likely to affect Black families - generational wealth saved getting diverted to long term care industry at end of life.

Table 2: Likelihood of Spend-Down Among Individuals Initially Non-Medicaid Enrolled by Demographic Characteristics and Length of Nursing Home Stay

Highlighted statistic showing that at 4 years after index nursing home stay, Black individuals have a 72.3% predicted probability of having undergone a spend down (difference 0.11, 95% CI 0.05-0.17), as compared to 61.2% for White individuals.

110

Hannah R. Abrams @hannahrabrams.bsky.social · 08/12/2025

Especially appreciated this note on terminology citing terms from #patientadvocate community @metavivor.bsky.social & Natl Coalition for Cancer Survivorship. Would love to hear from advocates in this space - what else should we be talking about here? @lisadtrice.bsky.social @morefor4.org

210